NCT00809510

Brief Summary

The purpose of this study is to evaluate the long-term safety and tolerability of ABT-089 in adults with mild-to-moderate Alzheimer's disease.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
63

participants targeted

Target at P50-P75 for phase_2

Geographic Reach
1 country

22 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 15, 2008

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 17, 2008

Completed
15 days until next milestone

Study Start

First participant enrolled

January 1, 2009

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Last Updated

September 2, 2011

Status Verified

September 1, 2011

Enrollment Period

5 months

First QC Date

December 15, 2008

Last Update Submit

September 1, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Safety Assessments (i.e., ECG, clinical laboratory tests, vital signs, weight, AE assessment, physical and brief neurological examinations)

    Month 1, 2, 4, 6

Secondary Outcomes (1)

  • ADAS-Cog, CIBIC-plus, MMSE, QoL-AD

    Month 1, 2, 4, 6

Study Arms (1)

1

EXPERIMENTAL
Drug: ABT-089

Interventions

20 mg ABT-089 taken once-daily for 6 months

1

Eligibility Criteria

Age55 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The subject was randomized into Study M06-876 and completed the study.
  • The subject must remain on the same dose of AChEI that was used during the M06-876 study.
  • The subject is in general good health, as judged by the investigator

You may not qualify if:

  • The subject is currently, or plans to participate in another experimental study during the course of this trial.
  • The subject anticipates a move outside the geographic area of the investigative site or is planning extended travel inconsistent with the recommended visit intervals.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (22)

Site Reference ID/Investigator# 16543

Phoenix, Arizona, 85006, United States

Location

Site Reference ID/Investigator# 16528

Sun City, Arizona, 85351, United States

Location

Site Reference ID/Investigator# 16524

Fresno, California, 93720, United States

Location

Site Reference ID/Investigator# 16520

San Diego, California, 92108, United States

Location

Site Reference ID/Investigator# 16521

Santa Monica, California, 90404, United States

Location

Site Reference ID/Investigator# 16533

Hamden, Connecticut, 06518, United States

Location

Site Reference ID/Investigator# 16516

Brooksville, Florida, 34601, United States

Location

Site Reference ID/Investigator# 16510

Deerfield Beach, Florida, 33064, United States

Location

Site Reference ID/Investigator# 16508

Delray Beach, Florida, 33445, United States

Location

Site Reference ID/Investigator# 16515

Miami, Florida, 33180, United States

Location

Site Reference ID/Investigator# 16545

Palm Beach Gardens, Florida, 33418, United States

Location

Site Reference ID/Investigator# 16541

Sunrise, Florida, 33351, United States

Location

Site Reference ID/Investigator# 16542

Tampa, Florida, 33613, United States

Location

Site Reference ID/Investigator# 16529

West Palm Beach, Florida, 33407, United States

Location

Site Reference ID/Investigator# 16526

Indianapolis, Indiana, 46260, United States

Location

Site Reference ID/Investigator# 16527

Eatontown, New Jersey, 07724, United States

Location

Site Reference ID/Investigator# 16523

Ridgewood, New Jersey, 07450, United States

Location

Site Reference ID/Investigator# 16532

New York, New York, 10021, United States

Location

Site Reference ID/Investigator# 16519

Winston-Salem, North Carolina, 27103, United States

Location

Site Reference ID/Investigator# 16525

Centerville, Ohio, 45459, United States

Location

Site Reference ID/Investigator# 16507

Wichita Falls, Texas, 76309, United States

Location

Site Reference ID/Investigator# 16509

Bennington, Vermont, 05201, United States

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

pozanicline

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Study Officials

  • Robert Lenz

    Abbott

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 15, 2008

First Posted

December 17, 2008

Study Start

January 1, 2009

Primary Completion

June 1, 2009

Last Updated

September 2, 2011

Record last verified: 2011-09

Locations